Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenalidomide + High-Dose Melphalan for Autologous Transplant in Multiple Myeloma
NCT01079936Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Mar 2010
- Primary completion
- Mar 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of lenalidomide in multiple myeloma (MM), sponsored by University of Texas MD Anderson Cancer Center. Started Mar 2010; status: completed.
02
Drugs
lenalidomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT01079936.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01079936.